{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-050005","form_type":"8-K","ticker":"GALT","cik":"0001133416","company_name":"GALECTIN THERAPEUTICS INC","filed_at":"2024-12-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.755322+00:00","generated_at":"2026-05-29T00:03:46.992961+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Galectin NAVIGATE trial: belapectin reduces varices by 48.9% in per-protocol but misses ITT primary endpoint","bullets":["In ITT (N=355), primary composite endpoint not statistically significant; varices incidence reduced 43.2% with 2mg/kg vs placebo.","In per-protocol (n=290), belapectin 2mg/kg showed 48.9% reduction in varices (p<0.05).","Safety profile favorable; adverse events comparable across cohorts, no drug-related SAEs.","Additional 36-month data from ~50 patients expected in Q1 2025.","Company will engage with potential partners to determine next steps."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-050005","json":"https://secwatch.observer/filing/0001140361-24-050005.json","markdown":"https://secwatch.observer/filing/0001140361-24-050005.md","text":"https://secwatch.observer/filing/0001140361-24-050005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133416/000114036124050005/0001140361-24-050005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133416/000114036124050005/ef20040433_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T00:03:46.992961+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}